Background
In recent years, red yeast rice (RYR) supplements have
encountered increasing research interest for their possible
lipid-lowering effects. Whereas the evidence in favor of
these products is still being developed and refined, dietary
supplement industries have proceeded without delay to
produce a number of RYR formulations. These food supplements are marketed and mediatized as a “natural” alternative to lipid lowering drugs and as a solution for
patients who experience statin-associated myalgia.